Altheos, Inc. is a venture-backed biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs.
Altheos, Inc. is focused on the development of a best-in-class next-generation eye drop treatment for glaucoma. The lead compound, ATA907, is a selective rho-kinase (ROCK) inhibitor developed specifically for topical treatment of glaucoma which Altheos licensed from a Japanese pharmaceutical company. The license also includes a series of additional promising highly active compounds for which the company has worldwide rights (except Japan and Korea). The company completed a $20MM series A financing led by Bay City Capital with participation from Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital.
Company Details
- Founded
- 2010
- Address
- South San Francisco, California
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Keywords
- drug development (ocular diseases).
- HQ
- South San Francisco, California
- Competitors
- Alteos.
Altheos Questions
Altheos's website is http://web.archive.org/web/20110207190010mp_/http://altheos.com/
Altheos's LinkedIn profile is https://www.linkedin.com/company/altheos-inc
Altheos's industry is
Pharmaceutical Manufacturing
Altheos's top competitors are
Alteos.
Altheos's categories are Pharmaceutical Manufacturing
Altheos's founding year is 2010
